News NICE recommends Celgene's Ozanimod to treat ulcerative colit... The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate to severe active ulcerative colitis (UC).
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.